B. Braun seeks World Bank loan to support construction of Indonesia parenterals plant

By Gareth Macdonald

- Last updated on GMT

B. Braun seeks World Bank loan to support construction of Indonesia parenterals plant

Related tags Asia-pacific

B. Braun has asked the World Bank for a €55m loan to support construction of a parenteral drug manufacturing facility it is building in Indonesia.

The loan – disclosed by the World Bank in December​ – is being sought to fund construction of the plant in Kota Bukit Indah, Indonesia.

A spokesman for B.Braun told us “we can confirm that we sought a loan from the World Bank for our Indonesia production plant project​.” 

The facility​ – construction of which began in May – will make sterile parenteral drug preparations. The project is expected to be completed next June.

According to a plan posted on the World Bank’s website the plant will feature production areas, warehousing space, offices, a chiller and cooling tower, a flammable and toxic building, a high pressure boiler, a domestic and fire water tank, bus shelter and car park.

The bank said that manufacturing operations will focus on production and packaging of parenteral preparations adding that the products will “supply the Indonesian market but may also be exported.”

B. Braun generated revenue of €840m ($916m) from the Asia-Pacific region in 2014, primarily from the sale of products made at its manufacturing facilities in Europe and in China, India, Japan, Malaysia and Vietnam.

The German firm’s total revenue last year was €5.4bn.

Related news

Show more

Related products

show more

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Related suppliers